Home » FDA Will Revise ADHD Drug Labels, But Stops Short of Black Box Warning
FDA Will Revise ADHD Drug Labels, But Stops Short of Black Box Warning
March 24, 2006
The FDA will soon implement an advisory panel’s recommendation to add label warnings to drugs that treat attention deficit/hyperactivity disorder (ADHD), said a top agency official. The panel stopped short of calling for the strictest black box warning.